COMP <GO>
INDV vs LLY // EV/EBITDA & P/E VALUATION
Indivior Pharmaceuticals Inc. (NASDAQ) VS. Eli Lilly and Company (NYSE) • 15-METRIC TALLY: INDV 4
— LLY 10
▲ EV/EBITDA & P/E VALUATION LEADER: INDV
LAST: $35.25 (+1.38%) • MKT CAP: $4.16B
valuation
13.4x
LAST: $1,373.70 (+6.63%) • MKT CAP: $1.29T
valuation
36.4x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (INDV VS. LLY)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | INDV | LLY | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 80.20% | 83.64% | -3.44 | LLY | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 62.20% | 32.36% | +29.84 | INDV | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | 13.4x | 36.4x | -23.02 | INDV | /valuation <GO> |
| Free Cash Flow Yield | -2.24% | 2.30% | -4.54 | LLY | /fcf-yield <GO> |
| Operating Margin | 21.10% | 40.21% | -19.11 | LLY | /operating-margins <GO> |
| Net Profit Margin | 16.90% | 31.90% | -15.00 | LLY | /net-margins <GO> |
| Revenue Growth (YoY) | 4.30% | 45.51% | -41.21 | LLY | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.49% | -0.49 | LLY | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 3.13 | 9.29 | -6.16 | LLY | /balance-sheet <GO> |
| Piotroski F-Score Quality | 5/9 | 9/9 | -4.00 | LLY | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | 6.77% | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 51.2 | 66.6 | -15.40 | LLY | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.15 | 0.51 | +0.64 | INDV | /macro-sensitivity <GO> |
| Forward P/E Multiple | 18.4x | 26.3x | -7.85 | INDV | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $4.16B | $1.29T | -$1.29T | LLY | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | INDV REV | LLY REV | INDV GROSS % | LLY GROSS % | INDV FCF | LLY FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $1.24B | $65.18B | 80.2% | 83.0% | -$93.0M | $16.81B |
| FY 2024 | $1.19B | $45.04B | 80.6% | 81.3% | $7.0M | $8.82B |
| FY 2023 | $1.09B | $34.12B | — | 79.3% | -$349.2M | $4.24B |
| FY 2022 | — | $28.54B | — | 76.8% | — | $7.59B |
| FY 2021 | — | $28.32B | — | 74.2% | — | $7.37B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
INDV // BETA 1.15
LLY // BETA 0.51